SynthesisFrontiers in endocrinology2026
New sights of spleen-preserving versus splenectomy in distal pancreatectomy for pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For resectable pancreatic neuroendocrine tumors (pNETs) located in the body or tail of pancreas that require surgery, distal pancreatectomy with splenectomy (DPS) is standard. While splenic-preserving distal pancreatectomy (SPDP) may reduce complications and provide additional benefits, its feasibility in pNETs remains uncertain. This study compares the perioperative outcomes of SPDP versus DPS for pNET patients. Methods: A comprehensive literature search was conducted in PubMed, Embase, and Web of Science included studies published before June 1, 2025. The analysis focused on primary endpoints of intraoperative blood loss (ml) and lymph nodes harvested, as well as secondary endpoints including operative time (min), transfusion, R0 resection, postoperative major complications (PMCs), postoperative pancreatic fistula (POPF), postoperative hemorrhage (PPH), hospital stay (day), lymph node metastasis (LNM), and reintervention. The pooled analysis is presented as odds ratios (OR) or mean differences (MD) with 95% confidence interval (CI). The protocol is registered on PROSPERO (CRD420251079167). Results: 4 retrospective studies involving 457 patients (226 with SPDP and 231 with DPS) were analyzed. 401 patients have well-differentiated G1/G2 tumors, and the majority of SPDP patients have small tumors. Compared to DPS, SPDP had less intraoperative blood loss (SMD, -0.50, 95% CI [-0.90 to -0.11], P = 0.01), fewer lymph nodes examined (MD, -3.30, 95% CI [-5.35 to -1.24], P = 0.002), shorter operative time (MD, -31.78 min, 95% CI [-57.98 to -5.58], P = 0.02), fewer PMCs (OR, 0.57, 95% CI [0.34 to 0.95], P = 0.03) and lower transfusion rates (OR, 0.25, 95% CI [0.07 to 0.83], P = 0.02). In terms of length of hospital stay, SPDP demonstrated more favorable outcomes (MD, -1.13 days, 95% CI [-2.02 to -0.24], P = 0.01). No significant differences were observed regarding R0 resection (OR, 1.40, 95% CI [0.43 to 4.58], P = 0.58), LNM (OR, 0.95, 95% CI [0.49 to 1.85], P = 0.88), or other perioperative outcomes. Conclusion: This study proposes that SPDP may represent a feasible option for selected patients with small, well-differentiated G1/G2 pNETs, suggesting a potential role in reducing surgical risks. These findings should be interpreted as hypothesis-generating, highlighting the need for further investigation. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/recorddashboard, identifier CRD420251079167.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.